Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 84

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 84
---
 Feuerstein, a Director of Alpha, holds voting and dispositive power over the securities held by Alpha. At the Closing, 37,304 RSUs issued by Kadimastem are expected to be exchanged for 232,686 RSUs of the combined company, and 175,600 Kadimastem options to purchase Kadimastem Ordinary Shares are expected to be exchanged for 1,095,317 options to purchase NLS Common Shares of the combined company. Q.What is the anticipated ownership of options, warrants and other outstanding equity awards that are anticipated to remain outstanding following the completion of the Merger? As of August28, 2025, the expected total amount of RSUs of Kadimastem that will be exchanged for RSUs of NLS is 37,304 RSUs of Kadimastem, which will equal to 232,686 RSUs of NLS at the Effective Time. All such RSUs have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 0.5% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. As of August28, 2025, the total amount of Kadimastem options that will be exchanged for NLS options at the Effective Time will be 175,600, which will be exchanged for 1,095,317 NLS options. All such options have been and shall continue to be owned by current and past officers and employees of Kadimastem and represent approximately 2.20% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. Additionally, NLS is required to make payments under a finder’s agreement of warrants to purchase $500,000 worth of NLS Common Shares with an exercise price per share equal to the price per NLS Common Share on Nasdaq immediately prior to the public announcement of such transaction. For more information, please see “ The Mer g er — NL S’s Background of the Merger.” Q.Who can help answer my questions? With regard to the NLS Meeting, shareholders of NLS who have questions may contact NLS by mail (NLS Pharmaceutics Ltd., Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -phar ma.com). xx SUMMARY OF THE PROXY STATEMENT / PROSPECTUS This summary highlights selected information from this proxy statement / prospectus and